Inventiva S.A.

0RNK · LSE

3.37EUR+0.02 (+0.60%)

Price History

Full chart

Market Stats

Previous Close3.35

Open3.51

Day Range3.33 – 3.55

52-Week Range2.75 – 6.19

Volume11.37K

Market Cap83.36M

P/E (TTM)0.00

Forward P/E0.00

EPS-1.27

Dividend Yield0.00%

Beta0.92

50-Day Avg3.57

200-Day Avg3.59

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company Details

CEOMr. Andrew Obenshain
Employees69
Headquarters50 rue de Dijon, Daix, France, 21121, UK
Websitehttps://inventivapharma.com

Leadership

Mr. Andrew ObenshainChief Executive Officer · b. 1974
Dr. Pierre Broqua Ph.D.Co-Founder · b. 1962
Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · b. 1965
Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · b. 1969
Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · b. 1966
Mr. Axel-Sven MalkomesChief Financial Officer · b. 1967
Ms. Susan ColesChief Legal Officer · b. 1966
Ms. Pamela HerbsterChief People Officer
Ms. Nazira Amra M.D.Chief Commercial Strategy Officer

Financials

Income Statement

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	5.08M	3.28M	4.87M	9.45M	4.80M	3.20M	7.00M	372.00K	4.19M	12.18M	23.16M	9.20M	4.48M
Growth (%)	-	-35.37%	+48.49%	+93.77%	-49.21%	-33.35%	+118.89%	-94.68%	+1027.42%	+190.39%	+90.19%	-60.29%	-51.26%
Cost of Revenue	1.68M	1.52M	1.40M	1.49M	1.24M	967.00K	-4.29M	846.00K	1.02M	995.00K	1.02M	3.59M	2.91M
Gross Profit	3.40M	4.63M	3.47M	7.96M	3.56M	2.23M	11.29M	-474.00K	3.18M	11.18M	22.15M	5.61M	1.57M
Gross Margin	66.89%	141.09%	71.18%	84.27%	74.23%	69.75%	161.35%	-127.42%	75.75%	91.83%	95.61%	60.99%	35.07%
Operating Expense	17.90M	21.11M	22.13M	24.91M	30.91M	36.94M	44.48M	31.20M	58.42M	73.91M	124.86M	105.08M	137.90M
Operating Income	-14.50M	-16.48M	-18.66M	-16.95M	-27.35M	-34.71M	-33.19M	-31.67M	-55.25M	-62.73M	-102.71M	-99.47M	-136.33M
Operating Margin	-285.53%	-502.08%	-382.86%	-179.50%	-570.17%	-1085.74%	-474.22%	-8513.71%	-1317.31%	-515.05%	-443.42%	-1081.49%	-3040.98%
EBITDA	-11.42M	-12.43M	-17.36M	-15.22M	-25.89M	-33.76M	-33.04M	-30.66M	-52.27M	-57.72M	-101.85M	-172.64M	-133.42M
EBITDA Margin	-224.73%	-378.48%	-356.19%	-161.13%	-539.66%	-1056.05%	-472.08%	-8242.47%	-1246.33%	-473.92%	-439.70%	-1876.97%	-2976.04%
Net Income	-7.13M	-7.49M	-8.82M	-7.05M	-19.08M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M	-354.14M
Net Income Margin	-140.46%	-228.26%	-181.00%	-74.59%	-397.81%	-1051.52%	-431.81%	-9037.37%	-1183.48%	-445.64%	-476.73%	-2002.74%	-7899.58%
R&D	12.75M	15.31M	18.75M	20.91M	25.72M	30.87M	32.73M	22.89M	47.70M	59.01M	107.69M	87.99M	87.04M
R&D as % of Total Revenue	250.99%	466.35%	384.70%	221.33%	536.25%	965.53%	467.72%	6151.88%	1137.36%	484.49%	464.94%	956.59%	1941.62%
Interest Expense	630	2.94K	6.06K	7.55K	8.00K	206.00K	19.00K	66.00K	142.00K	755.00K	5.22M	12.24M	33.62M
Interest Expense % of Total Revenue	0.01%	0.09%	0.12%	0.08%	0.17%	6.44%	0.27%	17.74%	3.39%	6.20%	22.55%	133.09%	750.01%

Balance Sheet

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	87.12M	73.13M	60.58M	48.86M	74.37M	79.81M	56.96M	137.89M	121.22M	115.72M	69.56M	118.62M	248.99M
Total Liabilities	28.11M	21.63M	17.81M	13.14M	12.47M	18.22M	15.57M	27.71M	33.12M	70.53M	101.59M	225.61M	278.03M
Total Equity	59.01M	51.51M	42.77M	35.72M	61.90M	61.60M	41.39M	110.18M	88.10M	45.19M	-32.03M	-107.00M	-29.05M
Cash	13.52M	17.14M	22.60M	24.87M	59.05M	56.69M	35.84M	105.69M	86.55M	86.74M	27.34M	96.56M	99.31M
Total Debt	160.39K	104.46K	698.00K	627.60K	482.00K	225.00K	115.00K	10.05M	10.12M	34.51M	54.08M	54.26M	59.42M
Net Debt	-13.36M	-17.03M	-21.90M	-24.24M	-58.57M	-56.47M	-35.73M	-95.63M	-76.43M	-52.22M	26.74M	-42.31M	-39.89M

Cash Flow

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-16.01M	-14.79M	-13.98M	-14.86M	-17.00M	-34.21M	-28.40M	-30.59M	-47.63M	-44.93M	-81.61M	-85.93M	-105.13M
Investing Cash Flow	18.37M	18.46M	18.85M	17.20M	6.17M	-420.00K	-826.00K	-8.56M	-1.79M	8.87M	-7.73M	8.74M	-133.19M
Financing Cash Flow	240.49K	-60.49K	591.84K	-70.86K	45.02M	32.27M	8.38M	111.67M	25.45M	37.27M	29.08M	145.59M	241.53M
Capital Expenditure	1.92M	1.29M	968.99K	227.94K	428.00K	549.00K	136.00K	292.00K	534.00K	561.00K	540.00K	333.00K	247.00K
Free Cash Flow	-17.93M	-16.08M	-14.95M	-15.09M	-17.43M	-34.76M	-28.54M	-30.88M	-48.16M	-45.49M	-82.15M	-86.26M	-105.38M
FCF to OCF	111.99%	108.73%	106.93%	101.53%	102.52%	101.60%	100.48%	100.95%	101.12%	101.25%	100.66%	100.39%	100.23%

Earnings

Report Date	Mar 31, 2020	Jun 30, 2020	Sep 25, 2026	Apr 1, 2027
EPS Estimate	-	-	-	-
EPS Actual	-0.23	-0.29	-	-
Surprise	-	-	-	-
Timing	-	-	After-hours	After-hours

Key Statistics & Ratios

Market Cap83.36M

Enterprise Value747.66M

Trailing P/E0.00

Forward P/E0.00

Price / Sales12.33

Price / Book0.00

EPS-1.27

Book Value0.25

Revenue (TTM)2.46M

Gross Profit (TTM)1.92M

EBITDA-149.06M

Profit Margin0.00%

Operating Margin-5337.32%

Return on Equity-989.05%

Return on Assets-42.69%

Shares Outstanding22.26M

Shares Float179.64M

Beta0.92

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%